Hikma Sues Eagle Over $3.5M Generic-Drug Rights Deal

Law360, New York (June 25, 2013, 4:29 PM EDT) -- Hikma Pharmaceuticals LLC sued Eagle Pharmaceuticals Inc. in New York federal court Monday, alleging Eagle had failed to win timely regulatory approval as required under a $3.5 million generic-drug rights transfer deal due to manufacturing problems it fraudulently concealed, then refused to refund the money.

According to the Jordanian drugmaker, Woodcliff Lake, N.J.-based Eagle had hidden problems in the development of the unspecified generic drug prior to Hikma agreeing to acquire the rights to the drug, then wrongly refused to refund the money paid under the...
To view the full article, register now.